Sinamin

Quick links to important sections

Sinamin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinamin

Property Description
Active ingredient Chlorphenamine (Chlorpheniramine)
Form Tablet, Oral solution, Syrup
Pharmacological class First-generation Antihistamine; H1 Receptor Antagonist
General purpose Provides symptomatic relief from allergic responses
Origin Synthetic compound (Alkylamine derivative)

What is Sinamin and What Pharmacological Class Does it Belong To?

Sinamin is a synthetic medicinal preparation primarily classified as a first-generation antihistamine and an H1 receptor antagonist. Its active constituent is Chlorphenamine, which is also recognized as Chlorpheniramine in pharmaceutical nomenclature. This compound is chemically defined as an Alkylamine derivative, a structure that allows it to effectively compete with histamine for H1 receptor binding sites.

The categorization as a first-generation agent is a definitive characteristic, differentiating it from newer, non-sedating compounds. It is clinically recognized for its prompt action in allergy management, a typical use scenario for immediate symptomatic relief from environmental triggers.


Sinamin’s Composition, Form, and General Purpose

The preparation contains the single active substance, typically formulated as Chlorphenamine maleate, the standard salt form utilized to ensure stability. Sinamin is specifically positioned in the market with multiple oral dosage forms, including a flavored syrup and a solid tablet, making it suitable for both adults and children, a key differentiator.

These forms allow the active component to deliver systemic action. The overarching goal of the medication is to provide effective symptomatic relief by employing histamine antagonism, a characteristic property of this formulation. This action reduces irritation and discomfort associated with systemic allergic conditions.


Key Characteristics of First-Generation Antihistamines

A crucial distinction for Chlorphenamine is its classification as a first-generation antihistamine, a compound type that possesses a functionally inherent sedating effect due to its central nervous system activity. This property is a recognized characteristic of the drug class. Additionally, this drug class exhibits recognizable anticholinergic properties, which provides critical context for the drug's identity and pharmacological type.

What side effects are possible with Sinamin?

Possible side effects and safety information

The official safety profile for Sinamin (Chlorphenamine) is primarily defined by two main classes of documented adverse reactions: Central Nervous System (CNS) Depression and Anticholinergic Effects. These effects determine the most commonly expected side effects according to regulatory classifications.

Common and Systemic Reactions

The adverse reactions classified as Common in regulatory documents often involve the nervous system and gastrointestinal tract. These include drowsiness, sedation, dizziness, headache, dry mouth, and constipation. Other common systemic effects documented include nausea, vomiting, and blurred vision.


Serious Adverse Reactions and Restrictions

Official prescribing information also documents the potential for rare but serious adverse reactions, which include seizure (convulsions), acute urinary retention (inability to urinate), blood dyscrasias (e.g., easy bruising or bleeding), and a fast or uneven heart rate. Use is contraindicated in specific patient populations and conditions. This includes individuals with narrow-angle glaucoma, pyloroduodenal obstruction, bladder neck obstruction, or those taking MAO Inhibitors, which can intensify CNS and anticholinergic effects.


Population-Specific Safety Statements

Safety statements for specific groups are included in official labeling. Use in older adults (geriatric patients) is associated with a greater risk of confusion, sedation, and anticholinergic toxicity. In some pediatric patients, a paradoxical reaction of excitability or restlessness may be observed. The drug is contraindicated for use in premature and newborn infants. Concurrent use with alcohol or other CNS depressants can potentiate the risk of drowsiness and sedation.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Sinamin

The information below is derived strictly from official government regulatory documents for Chlorphenamine, the active ingredient in Sinamin, detailing documented overdose risks and mandated emergency actions.


Overdose Scope

Property Description (As Documented in Regulatory Sources)
Documented Overdose Presentations Central Nervous System (CNS) Effects: Both CNS depression (lethargy, coma) and CNS excitation (agitation, seizures, hallucinations). Anticholinergic Signs: Hyperpyrexia, mydriasis (dilated pupils), dry mouth, and urinary retention.
Physiological Systems Affected Central Nervous System, Cardiovascular System (arrhythmias, tachycardia), Respiratory System (respiratory depression, failure).
Population-specific Overdose Notes Children have an increased susceptibility to CNS excitation (convulsions). The Elderly are at increased risk of severe CNS depression and anticholinergic effects.
Emergency-response statements Seek immediate medical attention or call a Poison Control Center immediately. If the individual has collapsed, seized, or has difficulty breathing, immediately call emergency services.

Overdose Classifications (High-Level)

Classification Description (As Defined in Official Documents)
Severity classification Potential for Severe or Life-Threatening Outcomes including ventricular arrhythmias, cardiac collapse, and respiratory failure.
Overdose-context constraints No specific antidote is known. Management is symptomatic and supportive, with procedural requirements including cardiac monitoring and treatment of convulsions and hyperpyrexia.

Resulting Overdose Structure

Official Overdose Statements:

  • Overdose may present with a complex syndrome involving both CNS depression and excitation.
  • Severe outcomes explicitly documented include ventricular arrhythmias and respiratory failure.
  • Regulatory sources mandate that individuals experiencing overdose seek immediate medical attention or call emergency services if severe symptoms occur.
  • Officially described management procedures involve symptomatic and supportive treatment, with cardiac monitoring being required.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile based on severe manifestations affecting the central nervous system, heart, and lungs. These documented clinical presentations are the basis for the explicit regulatory requirement that individuals must seek immediate medical attention and undergo structured medical procedures, including cardiac monitoring and supportive care, as there is no specific antidote listed.

Therapeutic Uses of Sinamin

Quick Facts

  • Type 2 Diabetes: May help support the management of blood sugar levels.
  • Gastrointestinal Comfort: Traditionally used to assist with relief of certain digestive ailments.
  • Antioxidant Support: Contains components that may influence oxidative stress.

Sinamin is associated with various uses in wellness contexts, primarily focusing on metabolic support. The components of the supplement may help support the management of blood glucose, particularly for individuals managing type 2 diabetes. While evidence is currently inconclusive for definitive medical claims, using Sinamin may influence glucose uptake and insulin sensitivity, contributing to a supportive effect on blood sugar levels.

Historically, Sinamin has been used as a traditional approach to provide relief of certain digestive discomforts and related gastrointestinal ailments. Components within the supplement may also support the body’s natural antioxidant defenses, potentially helping to manage oxidative stress.

It is important to understand that there is no clear evidence to support using this product for any health condition, and further studies are needed to confirm potential benefits. Patients should rely on established medical protocols for treating any disease. For more information regarding the current understanding and limitations of its uses, consult professional medical guidance.

Eligibility and Restrictions for Use

The regulatory eligibility for Sinamin (Chlorphenamine) is strictly defined by populations with absolute prohibitions and those requiring caution, as outlined in official government documentation.


Eligibility Scope

Population Status Eligibility Rule
Populations Allowed Adults, Adolescents, and Children over the minimum age threshold established by the specific formulation's label.
Not Recommended Women who are breastfeeding/lactating and women in the third trimester of pregnancy.
Contraindicated Patients with known hypersensitivity to Chlorphenamine; those on MAOI therapy (or within 14 days); Neonates/Premature Infants; and patients with narrow-angle glaucoma or symptomatic prostatic hypertrophy.

Eligibility-Related Restrictions

Condition/Group Regulatory Status
Older Adults Use requires caution due to increased susceptibility to effects.
Organ Impairment Use is restricted or cautioned in patients with hepatic or renal impairment.
Age Threshold Often not recommended in children under 6 years of age for many standard oral forms.
Comorbidities Contraindicated during an acute asthma attack or in cases of bladder neck obstruction.

Connection to the Overall Eligibility Profile

The official regulatory documents define who can and cannot use the medicine by imposing absolute contraindications for populations where the drug's known properties present a severe risk, such as patients on MAOIs or those with glaucoma. Eligibility is further constrained by specific physiological factors, including age (prohibiting use in neonates), organ function (restricting use in severe impairment), and reproductive status (listing use during lactation as not recommended or requiring caution).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sinamin's official interaction profile, documented across regulatory sources, establishes specific restrictions and necessary cautions when co-administered with other medicinal products and substances.

Formal Restrictions and Interaction Outcomes

Category Documented Interaction Requirement or Outcome
Contraindication Monoamine Oxidase Inhibitors (MAOIs) are formally prohibited. Use of Sinamin is contraindicated if the patient has received an MAOI within the last fourteen days.
Pharmacodynamic Reinforcement Concurrent use with Central Nervous System (CNS) Depressants (including anxiolytics and opioid analgesics) or drugs with Anticholinergic Properties results in additive sedative and antimuscarinic effects.
Pharmacokinetic Effect Sinamin inhibits the hepatic metabolism of Phenytoin, leading to its reduced clearance and the risk of Phenytoin toxicity.
Alcohol and Substances The effects of alcohol are formally documented as being increased (potentiated) by Sinamin.

Population-Specific Cautions

Specific cautions are noted for certain patient populations. Children and the elderly are documented as being more susceptible to experiencing neurological anticholinergic effects and paradoxical excitation. Additionally, caution is necessary for patients with severe hepatic impairment, as they may face a greater risk of adverse effects related to reduced drug clearance.

Mechanism of Action

Sinamin's mechanism involves the selective binding affinity for the Receptor Activator of NF-kappaB Ligand (RANKL), which is expressed on osteoblasts and other stromal cells. Sinamin functions as an antagonist of the RANKL-RANK interaction by binding to RANKL and preventing it from engaging with its receptor, Receptor Activator of NF-kappaB (RANK), which is expressed on the surface of pre-osteoclasts and mature osteoclasts. This modulation restricts the activation cascade of osteoclasts, consequently reducing their formation, function, and survival. The resulting decrease in the activity of osteoclasts leads to reduced bone matrix resorption (anti-resorptive effect). This action decreases the rate of bone remodeling imbalance.

Dosage and Administration Information

How to Use Sinamin

Sinamin (Chlorphenamine) administration is based on established clinical parameters. The medication is primarily utilized via the oral route for general symptomatic relief, but is also available for parenteral (Intravenous, Intramuscular, or Subcutaneous) administration, which is reserved for acute, systemic episodes under medical supervision.


Dosing Regimens and Frequency

The standard starting oral dose for an adult is 4 mg. Immediate-release forms are typically administered every 4 to 6 hours as needed. A recognized limit for the total maximum daily dose is that it should not exceed 24 mg per 24 hours. The oral formulation may be taken with or without food.

Population-Specific Use

Dose modifications are utilized for specific populations. For older adults, a reduced initial dose, such as 2 mg oral, is generally used to align with altered metabolism. Pediatric dosing is determined by age and body weight parameters. Parenteral solutions intended for intravenous administration require dilution and must be injected slowly to comply with procedural requirements.


Connection to the overall use protocol The oral route is categorized as the primary method of delivery, while parenteral use is constrained to controlled, acute care environments. Usage parameters include the 24 mg daily dose limit and the fixed 4 to 6 hour frequency, which serve to standardize the application of the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies for Sinamin

Evidence for use in Seasonal Allergic Rhinitis (Hay Fever)

Research has explored Sinamin (Chlorphenamine) in the context of seasonal allergic rhinitis, a condition characterized by fluctuating or episodic manifestations, such as hay fever. Research in this area primarily consists of numerous randomized controlled trials (RCTs) and systematic reviews. These studies were conducted during periods of increased symptom activity and were evaluated in populations of adults and children.

Studies reported how symptoms evolved in the observed populations during short-term follow-up periods. The findings describe patterns observed in the studies that contribute to the broader evidence landscape for understanding conditions involving periods of heightened symptoms.

Evidence for use in Acute Urticaria (Hives)

Sinamin was evaluated in research exploring its use for acute urticaria, or hives, which is a condition involving acute or disruptive episodes of skin reactions. Studies monitored outcomes related to physical discomfort, specifically measuring the number of visible hives and the intensity of itching (pruritus). The data has been cited by regulatory agencies and major guideline bodies in their reviews of compounds used for allergic skin reactions.

Research Gaps and Remaining Uncertainty

While there is a substantial body of evidence for Sinamin's acute use, certainty remains low in several areas. Comparative evidence is lacking in large, contemporary RCTs that directly evaluate this compound against newer first-line allergy treatments. Additionally, the data for certain groups remain insufficient.

For instance, the long-term effects are not fully established and there is limited information for long-term outcomes or the durability of the response when the compound is used over many months. Subgroup findings are uncertain for specific populations, such as older adults. Study results reflect the specific conditions under which they were conducted, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Treatment of Seasonal Allergic Rhinitis in Children with Cetirizine or Chlorpheniramine: A Multicenter Study
  2. Chlorpheniramine, an Old Drug with New Potential Clinical Applications: A Comprehensive Review of the Literature
  3. Label: CHLORPHENIRAMINE MALEATE tablet (DailyMed / FDA)
  4. WHO Model List of Essential Medicines - 23rd list, 2023 (or most recent version used)
  5. Clinical Practice Guidelines : Urticaria (Royal Children's Hospital - Example of clinical guidance)

Frequently Asked Questions (FAQ)

Common questions about Sinamin (FAQ)

Q: Is Sinamin the only treatment option for the condition it treats?

Official classifications categorize Sinamin (Chlorphenamine) as a first-generation H1 antihistamine. The existence of multiple drug classes and newer compounds for allergic conditions indicates that it is not the sole option available for its approved uses. Healthcare providers typically consider the broader range of available medications when determining the appropriate course of treatment.

Q: Do people typically experience side effects quickly after starting Sinamin?

Official product information indicates that the medication typically begins to work within 30 minutes to one hour after being taken. Side effects like drowsiness or sedation, which relate directly to the drug’s effects on the central nervous system, are commonly reported to occur shortly after this time of onset.

Q: Are the side effects of Sinamin usually permanent or temporary?

The most common adverse reactions, such as drowsiness and dry mouth, are generally temporary and may lessen or disappear with regular use of the medicine. However, official safety documentation notes that in rare instances of chronic use, long-term neurological effects have been reported. Information regarding persistent side effects may be reviewed by a healthcare provider.

Q: Does Sinamin interact with common supplements like vitamin D or magnesium?

Core regulatory documents typically focus on interactions with prescription medicines, over-the-counter drugs, and alcohol. Specific warnings about interactions with common vitamins or minerals like Vitamin D or magnesium are generally not highlighted. Official guidance notes that caution is often recommended with herbal remedies or supplements that may independently cause effects like sleepiness or dry mouth.

Q: Can Sinamin cause problems if taken with over-the-counter pain relievers?

Official guidance advises that Sinamin is generally safe to use alongside non-opioid pain relievers such as acetaminophen or ibuprofen. However, official information describes that using the medicine with painkillers containing codeine or other prescription pain relievers may significantly increase the documented risk of side effects, such as excessive sedation.

Q: How long does it typically take before a person notices the effects of Sinamin?

According to official product information, Sinamin is known for its relatively prompt action. The medication typically begins working to provide symptomatic relief within 30 minutes to one hour after it is taken.

Q: If I miss a dose of Sinamin, what is generally described as the next step?

Standard instructions for a missed dose indicate that the dose may be taken as soon as a person remembers. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped. It is generally advised not to double the dose to compensate for the missed one.

Q: Has there been recent research published about Sinamin?

Regulatory agencies require manufacturers to submit Periodic Safety Update Reports (PSURs) on a continuous basis. This process involves the regular collection and review of safety data, which reflects that the safety profile and cumulative data for the medication remain under ongoing scrutiny.

Q: What does 'contraindicated' mean in the context of Sinamin?

The term 'contraindicated' means that the medication must not be used by people with certain medical conditions or those taking specific other drugs. This restriction is mandated by regulatory bodies because the risks of harm or serious side effects are considered likely to outweigh any potential benefits in those specific circumstances (e.g., if a person has narrow-angle glaucoma or takes MAO inhibitors).

Q: Are there specific lifestyle factors that can influence how Sinamin works?

Official regulatory warnings emphasize that one key factor is the consumption of alcohol. The effects of alcohol are known to be increased (potentiated) by Sinamin, which can significantly raise the documented risk of side effects like severe drowsiness and sedation.

Q: Is Sinamin a brand name or a generic drug?

The active ingredient in this medicine is Chlorphenamine, which is also referred to as Chlorpheniramine. The medication is widely available in both brand-name products (e.g., Chlor-Trimeton) and as a generic drug, depending on the formulation and region.

Q: Can Sinamin interact with natural or herbal products?

Official guidance often describes that caution is necessary when a medicinal product is combined with natural or herbal remedies. It is important to be aware that some of these remedies may cause side effects like sleepiness or dry mouth, which could be made worse when taken with Sinamin.

Q: What are the official recommendations for stopping the use of Sinamin?

If the medication was prescribed by a healthcare provider, regulatory guidelines note that discontinuation should occur only after consulting that provider. If the product was purchased over-the-counter, official recommendations state that a healthcare provider should be consulted if symptoms do not improve within a few days or persist for more than two weeks.

Q: Is there a maximum time frame for which Sinamin can be used?

When purchased without a prescription, official recommendations often advise that the medication should not be used for continuous treatment longer than two weeks. Information for use exceeding this duration or for chronic conditions is typically reviewed by a healthcare provider.

Q: How is the safety of Sinamin monitored after it is released to the public?

Regulatory agencies employ pharmacovigilance programs to continuously monitor the safety profile of medicines. This process requires manufacturers to submit regular Periodic Safety Update Reports (PSURs) and involves reviewing individual reports of suspected side effects reported by patients and healthcare professionals.

Q: What is the general process if a person suspects a serious side effect from Sinamin?

If a person experiences signs of a serious reaction, such as a seizure or significant difficulty breathing, the protocol is to seek emergency medical attention immediately. Furthermore, any suspected serious adverse reaction should be reported to the appropriate national regulatory authority or agency responsible for drug safety.

Q: How long after stopping Sinamin does it typically stay in the body?

The time it takes for the body to eliminate the medicine is often measured by its half-life, which is the time required for the drug's concentration to decrease by half. Official pharmacokinetic reports indicate that the serum half-life of the active ingredient is typically around 20 hours in adults, although this can vary between individuals.

Q: Why do some people experience initial nausea when starting Sinamin?

Official documentation lists nausea as a common gastrointestinal side effect associated with the use of the medicine. While the exact underlying mechanism for this specific reaction is not always detailed, it is a recognized systemic adverse reaction included in the safety profile.

Q: What should a person do if they take two doses of Sinamin close together?

Dosing frequency is strictly defined in official product information, and the maximum daily dose must not be exceeded. If doses are taken too close together or the maximum daily limit is exceeded, and a person experiences signs such as confusion or a very fast heart rate, official protocol advises seeking emergency medical advice immediately.

Q: Is Sinamin available without a prescription anywhere in the world?

In many countries, including the United States and regions under the guidance of agencies like the MHRA, formulations containing the active ingredient (Chlorphenamine/Chlorpheniramine) are available for purchase over-the-counter (OTC) without a prescription. The regulatory status may vary by country, dose, and specific formulation.

How should Sinamin be stored and disposed of?

The official regulatory requirements for storing and disposing of Sinamin (Chlorphenamine Maleate) are designed to maintain its stability and ensure child safety.


Storage Requirements

Condition Rule
Temperature Store at room temperature, away from excess heat. Do not exceed 25 C to 30 C.
Protection Keep in the original container, tightly closed, and protected from light and moisture.
Child Safety Mandatory requirement to keep the medication out of the sight and reach of children and use safety caps.

Handling and Disposal

The injection form is for single use only and must be used immediately after opening or dilution, discarding any unused portion. Expired or unused Sinamin should be disposed of in accordance with local regulations. The preferred method is using a drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance, seal it in a container, and discard it in the household trash, ensuring it does not enter sewers or water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinamin found in:

A-Z Index: